(Q36066157)

12 August 2017

1 reference

title

Monoclonal antibody therapy of ovarian cancer (English)

1 reference

12 August 2017

1 reference

1 reference

Christopher F Nicodemus

series ordinal

1

1 reference

12 August 2017

Jonathan S Berek

series ordinal

2

1 reference

12 August 2017

publication date

1 February 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

87-96

1 reference

12 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Rituximab: ongoing and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Using antibodies in tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Tumor markers in the management of patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Biologic and Immunologic Therapies for Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.1.87

21 January 2018

Identifiers

DOI

10.1586/14737140.5.1.87

1 reference

12 August 2017

1 reference